<div><p>Objective</p><p>Based on drug-drug interaction, dose reduction of rifabutin is recommended when co-administered with HIV protease inhibitors for human immunodeficiency virus (HIV)-associated mycobacterial infection. The aim of this study was to compare the pharmacokinetics of rifabutin administered at 300 mg/day alone to that at 150 mg every other day combined with lopinavir-ritonavir in Japanese patients with HIV/mycobacterium co-infection.</p><p>Methods</p><p>Plasma concentrations of rifabutin and its biologically active metabolite, 25-<i>O</i>-desacetyl rifabutin were measured in 16 cases with HIV-mycobacterial coinfection. Nine were treated with 300 mg/day rifabutin and 7 with 150 mg rifabutin every other day combined with lopin...
Aims To evaluate the potential pharmacokinetic interaction between the HIV protease inhibitor saquin...
This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between az...
Contains fulltext : 59349.pdf (publisher's version ) (Open Access)Coadministration...
<div><p>Background</p><p>Rifampicin and protease inhibitors are difficult to use concomitantly in pa...
Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associate...
Background. Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given ...
Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associate...
BACKGROUND: Rifampicin and protease inhibitors are difficult to use concomitantly in patients with H...
Setting: Rifabutin (RBT) is reported to be as effective as and to have less inducing effect on cytoc...
Objectives: To evaluate the pharmacokinetic profile of ritonavir-boosted lopinavir in HIV-infected p...
Abstract Background Pharmacokinetic interactions betw...
Background. Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeu...
This study evaluated the tolerance and potential pharmacokinetic interactions between clarithromycin...
This study evaluated the tolerance and potential pharmacokinetic interactions between clarithromycin...
Study Objective. To characterize the bidirectional interaction between twice-daily nelfinavir and tw...
Aims To evaluate the potential pharmacokinetic interaction between the HIV protease inhibitor saquin...
This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between az...
Contains fulltext : 59349.pdf (publisher's version ) (Open Access)Coadministration...
<div><p>Background</p><p>Rifampicin and protease inhibitors are difficult to use concomitantly in pa...
Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associate...
Background. Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given ...
Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associate...
BACKGROUND: Rifampicin and protease inhibitors are difficult to use concomitantly in patients with H...
Setting: Rifabutin (RBT) is reported to be as effective as and to have less inducing effect on cytoc...
Objectives: To evaluate the pharmacokinetic profile of ritonavir-boosted lopinavir in HIV-infected p...
Abstract Background Pharmacokinetic interactions betw...
Background. Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeu...
This study evaluated the tolerance and potential pharmacokinetic interactions between clarithromycin...
This study evaluated the tolerance and potential pharmacokinetic interactions between clarithromycin...
Study Objective. To characterize the bidirectional interaction between twice-daily nelfinavir and tw...
Aims To evaluate the potential pharmacokinetic interaction between the HIV protease inhibitor saquin...
This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between az...
Contains fulltext : 59349.pdf (publisher's version ) (Open Access)Coadministration...